Aerie COO: Expanding innovation of glaucoma therapeutics

Conferences|GLAUCOMA 360

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

See more Glaucoma 360 coverage

Related Videos
Related Content

Alembic pharmaceuticals announces USFDA Final Approval for brimonidine tartrate ophthalmic solution 0.15%.

April 1st 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Driving with glaucoma: Steering clear of vision issues

March 28th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Alembic pharmaceuticals announces USFDA Final Approval for brimonidine tartrate ophthalmic solution 0.15%.

April 1st 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Driving with glaucoma: Steering clear of vision issues

March 28th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Alembic pharmaceuticals announces USFDA Final Approval for brimonidine tartrate ophthalmic solution 0.15%.

April 1st 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Driving with glaucoma: Steering clear of vision issues

March 28th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.